The Bayer P2X3 purinoreceptor antagonist, eliapixant (BAY1817080), is intended to treat various disorders associated with hypersensitive nerve fibers, including endometriosis. The hypothesis is that P2X3 receptor antagonism can inhibit cycles of pain causing neurogenic inflammation, causing pain, etc. modifying the underlying disease in [...]
< 1 minute read
Dec. 10, 2021
Eliapixant: A P2X3 Purinoreceptor Antagonist
eliapixant
oral P2X3 ion channel antagonist Ph. II, multiple settings (50-750 mg BID) from literature P2X3 antagonists Scientific Reports Bayer AG, Berlin, DE
Loading...
